Skip to main content

Market Overview

Evotec, Chinook Therapeutics Ink Development Pact For Chronic Kidney Diseases Therapies


Chinook Therapeutics Inc (NASDAQ: KDNY) and Evotec SE (OTCMKTS: EVTCY) have collaborated for the discovery and development of precision medicine therapies for patients with chronic kidney diseases (CKD).

  • Based on Evotec's proprietary comprehensive molecular datasets, Chinook and Evotec will jointly identify, characterize and validate novel mechanisms and discover and develop precision medicines.
  • The collaboration will utilize Evotec's PanOmics platform, which combines throughput proteomics, high throughput transcriptomics, and cell imaging with PanHunter, its data analysis platform.
  • Chinook will contribute drug discovery and development programs to the collaboration targeting rare kidney diseases such as IgA nephropathy and glomerular diseases.
  • Under the terms of the agreement, Chinook and Evotec will share drug discovery and pre-clinical development responsibilities.
  • Chinook will be responsible for the clinical development and commercialization of product candidates.
  • Evotec will receive an undisclosed upfront payment, research funding, milestone payments, and tiered sales-based royalties.
  • Price Action: KDNY shares closed 1.7% higher at $16.54, and EVTCY closed 0.8% lower at 77.45 on Friday.

Related Articles (EVTCY + KDNY)

View Comments and Join the Discussion!

Posted-In: Chronic Kidney DiseaseBiotech M&A News Health Care Contracts Small Cap General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at